Showing 1 - 6 results of 6 for search 'Chloe Orkin', query time: 0.02s Refine Results
  1. 1
    Prioritising community-defined interventions to address the health and well-being impact of the COVID-19 pandemic on racially minoritised communities in East London: results from an adapted James Lind Alliance priority setting partnership

    Prioritising community-defined interventions to address the health and well-being impact of the COVID-19 pandemic on racially minoritised communities in East London: results from a... by Isabelle Whelan, Chloe Orkin, Vanessa Apea, Suzannah Kinsella

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Mpox stigma in the UK and implications for future outbreak control: a cross-sectional mixed methods study

    Mpox stigma in the UK and implications for future outbreak control: a cross-sectional mixed methods study by Amy Paterson, Ashleigh Cheyne, Harun Tulunay, Chloe Orkin, Will Nutland, Jake Dunning, Jeni Stolow, Nina Gobat, Piero Olliaro, Amanda Rojek, Outbreak Stigma Assessment Expert Group

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study)

    Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucl... by Collins Iwuji, Laura Waters, Ana Milinkovic, Chloe Orkin, Julie Fox, Frank Post, Nicky Perry, Chloe Bruce, Natalie Dailey, Ye To, Stephen Bremner, Duncan Churchill, Anna Maria Geretti

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV

    Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV by Eric S. Daar, Chloe Orkin, Paul E. Sax, Debbie Hagins, Anton Pozniak, Kimberly Workowski, Cynthia Brinson, Juan Manuel Tiraboschi, Hui Liu, Chris Deaton, Cal Cohen, Sharline Madera, Jason T. Hindman, Moti Ramgopal

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV

    Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV by Anton Pozniak, Chloe Orkin, Yazdan Yazdanpanah, Axel Baumgarten, Karam Mounzer, Michelle L. D’Antoni, Hailin Huang, Hui Liu, Kristen Andreatta, Laurie A. VanderVeen, Christian Callebaut, Jason T. Hindman, José R. Arribas

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.

    Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. by Davide Corti, Johannes P M Langedijk, Andreas Hinz, Michael S Seaman, Fabrizia Vanzetta, Blanca M Fernandez-Rodriguez, Chiara Silacci, Debora Pinna, David Jarrossay, Sunita Balla-Jhagjhoorsingh, Betty Willems, Maria J Zekveld, Hanna Dreja, Eithne O'Sullivan, Corinna Pade, Chloe Orkin, Simon A Jeffs, David C Montefiori, David Davis, Winfried Weissenhorn, Aine McKnight, Jonathan L Heeney, Federica Sallusto, Quentin J Sattentau, Robin A Weiss, Antonio Lanzavecchia

    Published 2010-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: